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Available online 3 May 2019Background: Drug eluting stents with biodegradable polymers have been developed to address the risk of very
late adverse events. Long-term comparison data between the biodegradable polymer-coated biolimus-eluting
stent (BES; Nobori®) and the second-generation durable polymer-coated everolimus-eluting stent (EES;
XIENCE V® or XIENCE PRIME® or PROMUS™) in diabetic patients are scarce.
Methods: The COMPARE II trial was an investigator-initiated, multicenter, open-label, randomized, all-comers
trial which assigned patients undergoing percutaneous coronary intervention (PCI) in a 2:1 fashion to either
BES or EES. We analyzed the safety and efﬁcacy outcomes in diabetic patients at 5 year follow-up. The primary
pre-speciﬁed composite endpoint major adverse cardiac event (MACE) was deﬁned as cardiac death, non-fatal
target-vessel myocardial infarction (TV-MI), or clinically indicated target vessel revascularization (CD-TVR).
Results:Out of 2707 study patients, 588were diabetics (21.7%) of whom391were treatedwith BES and 197with
EES. At 5 years follow-up,MACE occurred in 87 patients (22.2%) in the BES group and in 34 patients (17.2%) in the
EES group (p= .34). Other safety and efﬁcacy endpoints did not differ between stent groups.
Conclusions:At 5 years follow-up, no differences in terms ofMACE aswell as all analyzed safety and efﬁcacymea-
sures, including stent thrombosis, between the biodegradable polymer-coated BES and the durable polymer-
coated EES in diabetic patients were observed.aasstad
mits).
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Diabetic patients account for approximately 20–30% of all patients
undergoing percutaneous coronary interventions (PCI) and experi-
enced higher rates of adverse events when compared to non-diabetics.
New-generation drug eluting stents (DES) have improved clinical
outcomes of patients undergoing PCIs compared to bare-metal stents
(BMS) and early generation DES and are, indeed, strongly recom-
mended in this high-risk subgroup. However, diabetes mellitus (DM)
still remains a powerful predictor of adverse clinical outcomes after
PCI with signiﬁcant late catch-up in major adverse cardiac events
(MACE) and target lesion revascularization (TLR) [1].Hospital, Maasstadweg
Abbott Vascular and
ears.
an open access article underSmall calibers of the target vessels, exuberant neointimal prolifera-
tion, prothrombotic state and diffuse vascular inﬂammation associated
with diabetic status have been advocated as the main drivers of recur-
rent ischemic events [2].
Permanent polymer of ﬁrst- and second-generation DES has been
suggested as a trigger for chronic inﬂammatory response and biode-
gradable polymers third-generation DES have been conceived to over-
come the safety issues of durable polymer comparators.
Recently, an ultra-thin struts biodegradable polymer sirolimus-
eluting stent has shown to have a similar efﬁcacy and safety proﬁle as
the current standard durable ﬂuoropolymer-coated everolimus-
eluting stent (EES) in this high-risk population [3]. However, these re-
sultswere obtained at 1 year follow-up andpotential beneﬁts of the bio-
degradable polymer DES are expected at long-term follow-up.
The multicenter randomized COMPARE II trial has compared the
safety and efﬁcacy outcomes of the new-generation durable polymer-
coated everolimus-eluting stent (EES; XIENCE V® or XIENCE PRIME®
or PROMUS™) with biodegradable polymer-coated biolimus-eluting
stent (BES; Nobori®) in a population-based all comer setting. Up tothe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Baseline characteristics.
BES (391) EES (197) p value
Age (mean age-yr) 69.55 ± 10.68 70.14 ± 10.89 0.53
Male n, (%) 273 (69.8) 141 (71.5) 0.66
Insulin treatment n, (%) 115 (29.4) 55 (27.9) 0.69
Hypertension n, (%) 282 (72.1) 140 (71.0) 0.78
Dyslipidemia n, (%) 279 (71.3) 146 (74.1) 0.48
Smoking n, (%) 252 (64.4) 118 (59.8) 0.38
Previous PCI/CABG n, (%) 114 (29.1) 56 (28.4) 0.94
Previous stroke (CVA/TIA/RIND) n, (%) 31 (7.9) 10 (5.0) 0.16
Chronic renal failure n, (%) 27 (6.9) 15 (7.6) 0.95
COPD n, (%) 35 (8.9) 23 (11.6) 0.38
ACS presentation n, (%) 202 (51.6) 99 (50.2) 0.74
Table 2
Procedural characteristics.
BES (391) EES (197) p value
Multivessel treatment n, (%) 77 (19.6) 38 (19.2) 0.74
Number of lesions treated 1.39 ± 0.73 1.48 ± 0.87 0.17
At least 1 RVD ≤ 2.75 mm n, (%) 151 (38.6) 84 (42.6) 0.75
At least 1 lesion length N 20 mm n, (%) 265 (67.7) 116 (58.8) 0.29
Lesions (593) Lesions (332) p value
Target vessel
RCA 321 (54.2%) 166 (50.2%)
LAD 141 (23.8%) 69 (20.8%)
LCX 115 (19.4%) 87 (26.4%)
LM 13 (2.3%) 8 (2.5%)
SVG 5 (0.8%) 3 (0.9%)
CTO n, (%) 12 (2.0) 9 (2.7) 0.32
In stent restenosis n, (%) 17 (2.8) 10 (3.0) 0.48
B2/C lesions n, (%) 274 (46.2) 142 (42.7) 0.75
Calciﬁcation moderate or severe n, (%) 201 (33.8) 107 (32.2) 0.56
Thrombus n, (%) 92 (15.5) 40 (12.0) 0.51
Ostial lesion n, (%) 86 (14.5) 38 (11.4) 0.72
Bifurcation n, (%) 32 (5.3) 25 (7.5) 0.74
Provisional 19 (60.0%) 13 (52%) 0.67
2 stents technique 13 (40.0%) 12 (48%) 0.58
Direct stenting n, (%) 205 (34.5) 115 (34.6) 0.11
Number of stents/lesion 1.44 ± 0.75 1.48 ± 0.87 0.49
RCA: Right coronary artery; LAD: Left descending artery; LCX: Left circumﬂex; LM: Left
Main; SVG: saphenous vein graft.
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to be similar between the two groups. Nevertheless, little is known
about very-long term outcomes of biodegradable polymer DES in dia-
betic patients.
The present subgroup analysis, according to diabetic status, displays
the ﬁve-years results of COMPARE II trial in this high-risk population.
2. Methods
The COMPARE II trial was an investigator-initiated, multicenter,
open-label, randomized, all-comers trial which assigned patients un-
dergoing PCI in a 2:1 fashion to either BES or EES. Details of the main
study with its inclusion and exclusion criteria as well as description of
study device and procedural methodologies have been previously pub-
lished [4]. All patients with medical treatment for diabetes were in-
cluded in this analysis and 5 year follow-up safety and efﬁcacy
outcomes were analyzed. The primary pre-speciﬁed composite end-
point major adverse cardiac event (MACE) was deﬁned as cardiac
death, non-fatalmyocardial infarction (MI), or clinically indicated target
vessel revascularization (CD-TVR).
The device-oriented endpoint of target lesion failure (TLF) was a
composite of cardiac death, non-fatal target vessel-related myocardial
infarction (TV-MI), and clinically driven target lesion revascularization
(CD-TLR). Stent thrombosis (ST) was deﬁned as ARC deﬁnition [5]. Pa-
tients were evaluated at 1, 6, 12, 24, 36 and 60months at the outpatient
clinic or by telephone, post or email. All sites were independently mon-
itored and reportable clinical events were adjudicated by an indepen-
dent committee. The study complied with the Declaration of Helsinki
and the institutional ethics committees of each participating institution
approved the protocol. All enrolled patients provided informed consent
before inclusion. The sponsor had no role in the study design, data col-
lection, data monitoring, data analysis or writing of the report.
2.1. Statistical analysis
The main study was designed as a non-inferiority trial at one year.
On the basis of other all-comer stentDES trialswith a non-inferiority de-
sign, such as LEADERS (delta b4•0%) and the RESOLUTE AC trial (delta
b3•5%), a non-inferiority margin of 4•0% was considered an acceptable
difference between the biolimus-eluting stent and everolimus-eluting
stent [6,7]. With a one-sided type 1 error of 0•05% and 5% lost at
follow-up, we calculated that 2700 patients would yield at least 90%
power to detect non-inferiority, according to the Newcombe-Wilson
score method.
The current analysis compared clinical outcomes according to dia-
betic status and stent type. Continuous variables are presented as
mean ± SD and binary variables as number and percentage. p values
for baseline characteristics were calculated with Chi-square or Fisher
exact test. Cumulative events rates were analyzed using the Kaplan-
Meier method. Hazard ratios were calculated using Cox regressions
and reportedwith 2-sides 95% conﬁdence intervals (CI). The interaction
between diabetic status and stent type was tested using Cox regres-
sions. Signiﬁcance level was set at p b .05. All analyses were performed
as intention-to-treat principle. Statistical analysis was performed with
SPSS version 20.0 (IBM, Armonk, New York).
3. Results
Out of 2707 patients enrolled in the Compare II trial and randomized
2:1 to BES or EES, 588 (21.7%)were diabetics. Among them, 391 patients
and 593 lesions received BES and 197 patients and 332 lesions received
EES. At 5 years follow-up, 6 patients (3%) in the EES group and7 patients
(1.8%) in the BES group were lost to follow-up or withdrew consent
(Fig. 1 Suppl).
As shown in Table 1, baseline characteristics were well balanced be-
tween the two treatment arms. Insulin dependent requiring diabetesmellitus (IDDM) was present in 115 patients (29.4%) allocated to BES
treatment and 55 patients (27.9%) allocated to EES treatment and the
rest of the patients were on oral hypoglycemic agents. Half of the pa-
tients presented with acute coronary syndrome (ACS) with a similar
distribution between the two groups. Angiographic and procedural
characteristics are shown in Table 2 and no signiﬁcant differences be-
tween BES and EES groups were detected.
Five-year clinical events rate are summarized in Table 1 Suppl and
shown in Fig. 1. The composite primary endpoint of cardiac death, TV-
MI and CD-TVR occurred in 87 patients (22.2%) in the BES group and
34 patients (17.2%) in the EES group (relative risk 1.12 [95% CI: 0.82,
1.55], p: 0.34) (Fig. 1). In ACS subgroup the rates of composite primary
endpoint in the BES and EES group were 20.3% and 20.2% (p: 0.65). In
non ACS subgroup MACE occurred in 46 (24.3%) patients of the BES
group and in 14 (14.3%) of the EES group (p: 0.24) (Table 1 Suppl,
Figs. 2,3,4 Suppl). Rates of device-oriented endpoint of TLF occurred in
75 patients (19.2%) in the BES group and in 32 (16.2%) in EES group (rel-
ative risk 1.18 [95% CI: 0.78, 1.79], p: 0.38.
Stent thrombosis rates up to 5 years were similar between groups at
all timepoints (Table 2 Suppl).
TheKaplan–Meier estimates showing the interplay between insulin-
requiring status and stent type are shown in Fig. 2. IDDM patients
showed higher rates of MACE compared to non IDDM patients, but no
signiﬁcant p of interaction has been found between the two factors.
Fig. 1. Kaplan-Meier for the composite primary endpoint.
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The main ﬁndings of the current sub-analysis of the Compare II trial
according to diabetic status are: 1) the biodegradable polymer coated
BES (Nobori) has a similar efﬁcacy and safety proﬁle as the durable
polymer coated EES (Xience or Promus) at 5 year follow up, 2) clinical
outcomes of diabetic patients, especially in the subset of insulin-
treated DM patients, continue to be worse compared to non-diabetics.
It is known that the diabetic status is associated with a higher risk
of both stent- and patient-related adverse events after PCI [8–10].Fig. 2. Kaplan Meier cumulative event curves of primary compositeSeveral mechanisms are involved in this pathophysiological process:
decreased insulin level combined with hyperglycemia may accelerate
oxidative stress, platelet activation, inﬂammation, apoptosis and
endothelial dysfunction and ultimately lead to progression of athero-
sclerotic lesions [11]. The use of second-generation DES has shown
promising results in terms of target vessel and target lesion revascular-
ization and ST,when compared toﬁrst generationDES even in this high-
risk subgroup of patients [11]. However, the event rates of diabetic
patients remain considerably higher compared to the general
population.endpoint according to stent type and insulin-requiring status.
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have been conceived to mitigate the device-related risk of recurrent
events. By avoiding the persistent vascular injury related to polymer
remnants within the arterial wall, newer-generation DES may offer po-
tential advantages over durable polymer DES.
Todate, long term follow-up data comparing biodegradable polymer
with durable polymer-coated ﬁrst-generation DES in diabetic patients
are available from a pooled analysis of three randomized trials (ISAR-
TEST 3, ISAR-TEST 4 and LEADERS) [12]. At 4 years, biodegradable poly-
mer DES were associated with similar incidence of primary endpoint of
ﬁrst generation durable polymer coated sirolimus eluting stent but a
statistically signiﬁcant reduction in stent thrombosis occurred in the
former group after one year. However, second generation durable poly-
mer DES with new platform design, more biocompatible polymer coat-
ing, thinner struts and different antiproliferative agents have
signiﬁcantly lowered the incidence of adverse events, including ST,
also in diabetic patients [13–15].
Five years results in the general population of the Compare II trial
showed similar clinical outcomes between the newer-generation
durable polymer-coated EES and biodegradable polymer-coated BES.
Promising beneﬁts of the biodegradable polymer DES were expected
at long term follow and potentially magniﬁed in diabetic patients.
Nevertheless, in our analysis no differences between the two treatment
arms in the diabetic subgroup have been detected. Overall, our results
were obtained in the context of rather large percentage of IDDM
patients, ACS presentation and multivessel treatment, providing
remarkable evidence of the comparable efﬁcacy and safety of the two
devices in a population with high-risk proﬁles and complex lesion
characteristics. Indeed, despite the low percentages of bifurcations le-
sions treated known to be responsible for higher rates of TLR at long
term follow-up, almost half of the lesions included were classiﬁed B2/
C according to AHA/ACC deﬁnition [16].
The present study represents the ﬁrst analysis on long-term out-
comes of diabetic patients treated with biodegradable polymer DES
compared to newer generation durable polymer DES. Moreover the rel-
evant number of enrolled patients allowed a further analysis according
to insulin-requiring diabetic status. In line with previous results, we
found that insulin-treated diabetic patients experienced higher adverse
event rates than non-insulin requiring diabetic patients. However, we
failed to prove an interplay between DES type and insulin treatment;
thus conﬁrming aworse clinical outcomes in IDDMpatients irrespective
of stent type.
Nevertheless, biodegradable polymer DES are differentiated by strut
thickness, polymer composition, distribution and load as well as the
time course for polymer resorption. Thick-struts devices have been as-
sociatedwith higher rates of luminal ﬂow turbulence and thrombus for-
mation compared to thin-struts devices [12,17]. Factors, other than
polymer may indeed play a role in the risk of ST. Subgroup analysis of
diabetic patients in the BIOSCIENCE trial showed similar clinical out-
comes between ultrathin struts polymer sirolimus eluting stents and
durable polymer EES at 1 year follow up, thus challenging the concept
of biodegradable polymer coated even with the newer ultrathin struts
devices [3].
However, the cumulative pathophysiological sequelae of DMon car-
diovascular event rates highlight the caveat of assessing short-term PCI
outcomes in these high-risk group patients. Hence, longer follow up are
needed to conﬁrm the absence of beneﬁts of newer biodegradable poly-
mer devices.
5. Study limits
Despite being rigorously conducted, this analysis has important
limitations.
First, the diabetic status was not a pre-speciﬁed parameter for ran-
domization. Although baseline and procedural characteristics were not
statistically signiﬁcant different between the two stent types in thediabetic subpopulation, no correction for differences in this analysis
were made. Therefore, the results of the subgroup analysis should be
considered as hypothesis-generating and require further investigation
in a properly powered and prospectively randomized trial.
Second, this trial aimed to compare the Nobori biodegradable
polymer-coated BES compared to the permanent polymer-coated EES.
Recent trials have investigated very-thin struts biodegradable polymer
coated DES but have failed to ﬁnd signiﬁcant differences between the
currently available devices in terms of angiographic and clinical out-
comes. However potential beneﬁts ofmore recent devices could emerge
at longer follow-up.
6. Conclusions
This is the ﬁrst analysis on long-term outcomes between the Nobori
biodegradable polymer-coated BES compared to the current standard
permanent polymer-coated EES in medically-treated diabetic patients.
At 5 years follow-up, no difference in terms of MACE and other efﬁcacy
and safety measures were detected between the BES and EES groups.
Our data conﬁrmed higher rates of adverse events in diabetic pa-
tients and, therefore, there is a continuing need for the most effective
coronary stent in this high-risk population.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.ijcard.2019.04.054.
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